Phoenix Pharmaceuticals 社では，多数のペプチドホルモン測定用 ELISA Kit の取り扱いがございます。商品リストはこちらをご覧下さい。
Gila Monster は年に 4 回しか採餌しません。採餌しない時はインスリンの分泌を停止させ，膵臓の活動を停止させています。Gila Monster が採餌を開始する時期になると，Exendin-4 というホルモンを分泌させ膵臓の活動を復活させます。 Exendrin-4 (Heloderma suspectum) RIA I
Catalog No.: RK-070-94*
Linear Range: 100-800 pg/ml (10-80 pg/tube)
Sensitivity ED50 : 230 pg/ml (23 pg/tube)
 | | Displacement Curve for Phoenix's Exendin-4 Antibody
Crossreactivity of Exendrin-4 antibody with Exendrin-4 and its related peptide
 |
| Ultra-Sensitive Exendin-4 RIA Kit
Catalog No.: RK-070-94-U*
Linear Range : 20-200 pg/ml
IC50 : 100-140 pg/ml
 | | ＊放射性物質を含む製品のため，弊社では取り扱いできません |
| 
Ligands and receptor constructs used in this work. A, aligned amino acid sequences of several GLP-1R peptide ligands. B, schematic representation of the wild type rat GLP-1R (rGLP-1R) and the two truncated rat receptors used in this study, rNT-TM1 and 6H-rNT. The N-terminal domain is represented by gray ovals, and transmembrane helices are shown as gray cylinders. The expression of rGLP-1R and rNT-TM1 in a mammalian system is indicated by the putative glycosylation shown with the two Y-shaped symbols. The 6H-rNT protein was expressed in a bacterial system and lacks glycosylation but contains a His6 tag (HHHHHH) close to the N terminus.
Lopez de Maturana R. J Biol Chem. 2003 Mar 21; 278(12):10195-200 |
| 
Morning-fed blood glucose and plasma insulin in wild-type C57BL/6 mice treated with saline, exendin-4 (Ex-4), STZ, or STZ+Ex-4. Blood glucose was significantly lower from day 9 to day 29 in STZ+Ex-4 mice compared with glucose in mice receiving STZ alone (p < 0.05), whereas fed plasma insulin level measured at day 30 was significantly higher in STZ+Ex-4 mice versus STZ alone (*, p < 0.05); n = 10 mice per each experimental group. C, control (saline).
Yazhou Li, et al. J. Biol. Chem., Vol. 278, Issue 1, 471-478, January 3, 2003 |
| N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity
Glucagon-like peptide-1(7-36)amide (GLP-1) possesses several unique and beneficial effects for the potential treatment of type 2 diabetes. However, the rapid inactivation of GLP-1 by dipeptidyl peptidase IV (DPP IV) results in a short half-life in vivo (less than 2 min) hindering therapeutic development. In the present study, a novel His(7)-modified analogue of GLP-1, N-pyroglutamyl-GLP-1, as well as N-acetyl-GLP-1 were synthesised and tested for DPP IV stability and biological activity. Incubation of GLP-1 with either DPP IV or human plasma resulted in rapid degradation of native GLP-1 to GLP-1(9-36)amide, while N-acetyl-GLP-1 and N-pyroglutamyl- GLP-1 were completely resistant to degradation. N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 bound to the GLP-1 receptor but had reduced affinities (IC(50) values 32.9 and 6.7 nM, respectively) compared with native GLP-1 (IC(50) 0.37 nM). Similarly, both analogues stimulated cAMP production with EC(50) values of 16.3 and 27 nM respectively compared with GLP-1 (EC(50) 4.7 nM). However, N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 exhibited potent insulinotropic activity in vitro at 5.6 mM glucose (P<0.05 to P<0.001) similar to native GLP- 1. Both analogues (25 nM/kg body weight) lowered plasma glucose and increased plasma insulin levels when administered in conjunction with glucose (18 nM/kg body weight) to adult obese diabetic (ob/ob) mice. N-pyroglutamyl- GLP-1 was substantially better at lowering plasma glucose compared with the native peptide, while N-acetyl- GLP-1 was significantly more potent at stimulating insulin secretion. These studies indicate that N-terminal modification of GLP-1 results in DPP IV-resistant and biologically potent forms of GLP-1. The particularly powerful antihyperglycaemic action of N-pyroglutamyl-GLP-1 shows potential for the treatment of type 2 diabetes.
Green BD, Endocrinol. 2004 Mar;180(3):379-88. |
| 
Morning-fed blood glucose and plasma insulin in wild-type C57BL/6 mice treated with saline, exendin-4 (Ex-4), STZ, or STZ+Ex-4. Blood glucose was signifi cantly lower from day 9 to day 29 in STZ+Ex-4 mice compared with glucose in mice receiving STZ alone (p < 0.05), whereas fed plasma insulin level measured at day 30 was signifi cantly higher in STZ+Ex-4 mice versus STZ alone (*, p < 0.05); n = 10 mice per each experimental group. C, control (saline).
Yazhou Li, et al. J. Biol. Chem., Vol. 278, Issue 1, 471-478, January 3, 2003 |
| 
Proliferative and Antiapoptotic Effects of GLP-1 and GLP-2 in the Pancreas and Intestine, respectively. GLP-1 stimulates cell proliferation in pancreatic ductal cells and islets, and exerts antiapoptotic actions on islet s-cells and neurons. GLP-2 stimulates intestinal crypt cell proliferation and inhibits apoptosis in the crypt and enterocyte compartments of the gut epithelium.
Drucker DJ. Mol Endo 17(2):161-171. 17 (2) | ■価 格 |
| [掲載日情報：2009/11/24 現在] |
| ● |
お問い合わせ先 |
 |
テクニカルサポート（試薬担当）
[TEL] 03-5684-1620 [FAX] 03-5684-1775
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。
|
|
|
|
|
|
